DEXMEDETOMIDINE SANDOZ (Sandoz Pty Ltd)
Product name
DEXMEDETOMIDINE SANDOZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
168 working days (255)
Active ingredients
dexmedetomidine (as hydrochloride)
Registration type
New generic medicine
Indication
DEXMEDETOMIDINE SANDOZ (concentrated injection vial) is indicated for:
ICU Sedation
For sedation of initially intubated patients during treatment in an intensive care setting.
Procedural Sedation
For sedation of non-intubated patients prior to and/or during surgical and other procedures.